Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • BIOBUSINESS BRIEFS

Stock price effects of breakthrough therapy designation

  1. David Hoffmann

    1. Institute of Molecular Biotechnology, Vienna, Austria.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Shane Van Dalsem

    1. School of Business, Washburn University, Topeka, KS, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Frank S. David

    1. Pharmagellan, Milton, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Since 2012, the FDA has awarded ‘breakthrough therapy designation’ (BTD) to drug candidates in clinical development that aim to treat serious diseases and have shown preliminary evidence of substantial effects. BTD provides sponsors with more frequent regulatory interactions and senior-level involvement during trial design and execution, submission and review. Prior studies have found that the term ‘breakthrough’ leads the public (JAMA Intern. Med. 175, 1856–1858; 2015) and physicians (JAMA 315, 1516–1518; 2016) to have over-optimistic views of a drug’s efficacy. The effect of BTD on investors’ perceptions of recipient firms, however, has not previously been examined.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 165 (2019)

doi: https://doi.org/10.1038/d41573-019-00019-6

Supplementary Information

  1. 41573_2019_CM16440414_MOESM1_ESM

Competing Interests

F.S.D. works for Pharmagellan, an advisory firm that provides paid consulting services to pharmaceutical and biotechnology companies in areas related to the topics covered in this article.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links